我要投票 朗迪Reneed在补钙行业中的票数:419
· 外 推 电 报 ·
2025-05-29 20:40:27 星期四

【朗迪Reneed是哪个国家的品牌?】

朗迪Reneed是什么牌子?「朗迪Reneed」是 北京振东康远制药有限公司 旗下著名品牌。该品牌发源于北京市,由创始人李昆在2003-11-07期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力朗迪Reneed品牌出海!将品牌入驻外推网,定制朗迪Reneed品牌推广信息,可以显著提高朗迪Reneed产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

钙营养补充剂品牌,主打维生素矿物质钙补充剂类药物,集研发、生产、销售于一体的集团化现代综合制药企业


北京振东康远制药有限公司始建于2003年10月,是国内较大的具有自主品牌的维生素矿物质钙补充剂类药物生产企业,是一家集研发、生产、销售于一体的集团化现代综合制药公司,是中国补钙药物的佼佼者和先锋。公司产品遍布全国,公司“朗迪”牌碳酸钙D3片(II)和碳酸钙D3颗粒已成为中国钙补充剂类药品市场的主流。公司2015年与上市公司振东集团山西振东制药股份有限公司强强联合,完成重大重组,实现了跨跃式发展。

公司于2009年进入中国钙制剂市场,旗下现有7家直属或控股的制药公司、2家直属药物研发公司及多家医药贸易公司,在30多个城市设立了办事机构,有数千家合作伙伴,累计总投资超过10亿元,全国有数千名员工为康远工作。

公司位于北京市昌平区西部约15公里的北京市昌平区流村工业园内,隶属中关村科技园昌平园。该厂区自2012年开始建造,总投资近亿元,按照新版欧盟GMP标准及中国GMP标准进行规划、设计和建设施工,配有国际前沿的制粒、干燥、混合、压片、包装等片剂、硬胶囊剂、颗粒剂生产线及软胶囊剂生产线,该项目已于2014年通过了BFDA组织的GMP认证,并获得片剂、硬胶囊剂、颗粒剂、软胶囊剂GMP证书。项目年生产能力近百亿片(粒、袋)。该项目的建成使康远制药一跃成为国内维生素矿物质钙补充剂类药物较大生产企业。

公司发展过程中始终以“构建国人健康骨骼”为已任,以“树民族工业品牌,为中国制药争光”为使命,为中国钙制剂的发展做出了较大的贡献,大大改善了亿万国人的生活质量。康远人负有共同的使命,遵循一致的价值观,始终秉承“济世安康、立勋鸿远”宗旨来服务社会、回报社会。目前公司年营业收入达数十亿元,年上缴税金数亿元。随着公司高速发展和对未来中国经济和全球钙制剂市场发展前景充分信心,北京振东康远制药正不断加快创新、运筹帷幄、酝酿百年规划,未来的康远终将成为一家拥有精良技术和设备、管理成熟的世界制药公司。


英文翻译:Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd., a brand of calcium supplements, is a group modern comprehensive pharmaceutical enterprise integrating R & D, production and sales. It was founded in October 2003. It is a large domestic manufacturer of vitamin and mineral calcium supplements with its own brand, integrating R & D, production and sales Group modern comprehensive pharmaceutical company is the leader and pioneer of calcium supplements in China. The company's products are all over the country, and its "landi" brand calcium carbonate D3 tablets (II) and calcium carbonate D3 particles have become the mainstream of China's calcium supplements market. In 2015, the company and the listed company Zhendong Group Shanxi Zhendong Pharmaceutical Co., Ltd. jointly completed major restructuring and achieved a leap forward development. In 2009, the company entered the calcium preparation market in China. At present, it has 7 pharmaceutical companies directly under or controlled by the company, 2 pharmaceutical research and development companies directly under the company and many pharmaceutical trading companies. It has set up offices in more than 30 cities, thousands of partners, with a total investment of more than 1 billion yuan, and thousands of employees working for Kangyuan. The company is located in Liucun Industrial Park, Changping District, Beijing, about 15km away from the west of Changping District, Beijing. The plant has been constructed since 2012, with a total investment of nearly 100 million yuan. It is planned, designed and constructed in accordance with the new version of EU GMP standard and China GMP standard. It is equipped with internationally cutting-edge tablet, hard capsule, granule production line and soft capsule production line. The project has passed the GMP certification organized by bfda in 2014, and has obtained tablet GMP certificate of hard capsule, granule and soft capsule. The annual production capacity of the project is nearly 10 billion pieces (grain and bag). With the completion of the project, Kangyuan pharmaceutical has become a large domestic manufacturer of vitamin, mineral and calcium supplements. In the development process of the company, we always take "building healthy skeleton of Chinese people" as our responsibility, take "building national industrial brand, winning honor for Chinese pharmaceutical" as our mission, and have made great contribution to the development of Chinese calcium preparation, greatly improving the quality of life of hundreds of millions of Chinese people. Kangyuan people have a common mission, follow the same values, and always adhere to the tenet of "helping the world and health, and making contributions to Hongyuan" to serve and repay the society. At present, the company's annual operating revenue is billions of yuan, and the annual tax payment is hundreds of millions of yuan. With the rapid development of the company and full confidence in the future development of China's economy and the global calcium preparation market, Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd. is constantly accelerating innovation, strategizing and brewing a hundred year plan. In the future, Kangyuan will eventually become a world pharmaceutical company with excellent technology and equipment and well managed.

本文链接: https://www.waitui.com/brand/52bc17e3b.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

“宇石空间”完成天使+轮融资

36氪获悉,火箭研发与制造商“宇石空间”近日宣布完成近亿元天使+轮融资,此轮融资由千乘资本领投,华仓资本等机构跟投,老股东麟阁创投继续追加投资,所筹资金将用于公司火箭产品研发、生产试验基地的持续建设和团队人员扩充。

41分钟前

Meta反垄断案庭审终结,命运系于法官裁决

Meta已在法庭上完成对美国联邦贸易委员会(FTC)“垄断指控”的全部抗辩。如今,这家科技巨头的命运——是否面临拆分——全系于一名联邦法官之手。长达七周的庭审于5月27日收官,双方获四个月时间提交书面陈词。随后,美国地方法官詹姆斯·博阿斯伯格将裁定:Meta是否在社交媒体市场构成非法垄断,其主导地位是否源于十余年前对Instagram与WhatsApp的收购。目前尚不清楚博阿斯伯格何时会作出裁决,不过裁决结果可能在年底前公布。(新浪财经)

41分钟前

Kohl's百货季度亏损小于预期,维持全年目标

美国百货连锁企业Kohl‘s(Kohl’s)周四公布优于预期的第一季度业绩后,维持了全年预测。尽管关税导致需求波动,该公司仍寄望于转型努力扭转局面。公司维持全年销售额预计下降5%至7%的目标,以及每股收益10美分至60美分的预期。(新浪财经)

41分钟前

中油资本:公司目前暂不涉及稳定币相关业务

36氪获悉,中油资本在互动平台表示,公司目前暂不涉及稳定币相关业务。公司将对相关领域政策动态保持关注及研究,依法合规、审慎稳健开展各项业务。

41分钟前

先导智能:已推出PVD镀膜等复合集流体创新制造方案,相关设备已获得客户订单

36氪获悉,先导智能在互动平台表示,在复合集流体领域,公司在铜箔、铝箔等不同工艺路线的设备端具备成熟技术储备,并已推出PVD镀膜、水电镀等复合集流体创新制造方案。相关设备现已获得了客户订单,并得到了来自客户的高度认可。

41分钟前

本页详细列出关于朗迪Reneed的品牌信息,含品牌所属公司介绍,朗迪Reneed所处行业的品牌地位及优势。
咨询